Posted by Michael Wonder on 28 Apr 2026
Scancell receives FDA fast track designation for iSCIB1+ in advanced melanoma
28 April 2026 - Scancell Holdings announces that the US FDA has granted fast track designation for its lead ImmunoBody iSCIB1+ for the treatment of advanced melanoma.
Initiation of the registrational Phase 3 trial with iSCIB1+ in advanced melanoma anticipated in H2, 2026
